News | July 01, 2021
Zydus applies to the DCGI for EUA to launch ZyCoV-D
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
The government has taken all the effective measures to make healthcare affordable
Subscribe To Our Newsletter & Stay Updated
